DUKECATHR Dataset Dictionary

Similar documents
SUPPLEMENTAL MATERIAL

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

Acute Coronary Syndrome

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM

Supplement materials:

Lnformation Coverage Guidance

APPENDIX F: CASE REPORT FORM

Difficult Data Definitions and Scenario s

Chapter 4: Cardiovascular Disease in Patients With CKD

Preoperative Cardiac Risk Assessment: Approach & Guidelines

EACTS Adult Cardiac Database

Supplementary Table S1: Proportion of missing values presents in the original dataset

Supplement Table 1. Definitions for Causes of Death

Common Codes for ICD-10

Form 136 WHI WOMEN S HEALTH INITIATIVE HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Listing Form: Heart or Cardiovascular Impairments. Medical Provider:

February 25, WHI Heart Failure Data Summary. A. Original WHI outcome (referred to as CHF)

Chapter 4: Cardiovascular Disease in Patients With CKD

Patient characteristics Intervention Comparison Length of followup

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept

Supplementary Online Content

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

4. Which survey program does your facility use to get your program designated by the state?

MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

The Muscatine Study Heart Health Survey

ANNUAL FOLLOW-UP QUESTIONNAIRE

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

ALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Acute Myocardial Infarction

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Process Measure: Screening for Adult Obstructive Sleep Apnea

HAAD quality KPI; waiting time

The ACC 50 th Annual Scientific Session

Exercise Prescription for Patients with CHF

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

The American Experience

REPORT ON ADULT PERCUTANEOUS CORONARY INTERVENTIONS (PCI) IN ONTARIO OCTOBER SEPTEMBER 2011

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Chapter 4: Cardiovascular Disease in Patients with CKD

Supplementary Table 1. Details of the components of the primary composite endpoint

Coronary Artery Disease: Revascularization (Teacher s Guide)

Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Supplementary Online Content

Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

ARIC. HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM with SUPPLEMENTAL INFORMATION

REPORT ON ADULT CARDIAC SURGERY IN ONTARIO

Supplementary Online Content

The MAIN-COMPARE Registry

Clinical Trial Synopsis TL-OPI-516, NCT#

Conflicts of Interest. Evaluation of Cardiac and Pulmonary Risk in the Preop Patient. Introduction. Risk Assessment. Risk Assessment: RCRI

Anatomy of the Heart and the. ICD-10 Codes

Improving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

12 Lead ECGs: Ischemia, Injury & Infarction. Kevin Handke NRP, FP-C, CCP, CMTE STEMI Coordinator Flight Paramedic

Pre-Operative Services Teaching Rounds 3 Jan 2011

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Continuing Medical Education Post-Test

JAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals)

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)

PCI Data Dictionary Procedures from January 1, 2010

CCRN Review Cardiovascular

2017 Cardiology Survival Guide

EACTS Adult Cardiac Database

Detailed Order Request Checklists for Cardiology

PROMUS Element Experience In AMC

Consensus Core Set: Cardiovascular Measures Version 1.0

Heart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients

Chapter 9: Cardiovascular Disease in Patients With ESRD

(For items 1-12, each question specifies mark one or mark all that apply.)

10. Definition of cardiovascular disease 10.1 Nosologic definitions Acute myocardial infarction: myocardial cell death due to prolonged ischaemia 62.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA

The ESC Registry on Chronic Ischemic Coronary Disease

Presenter: Steven Brust, HCS-D, HCS-H Product Manager, Home Health Coding Center

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Chapter 14 Cardiovascular Emergencies Cardiovascular Emergencies Cardiovascular disease has been leading killer of Americans since.

Women and Vascular Disease

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Adult Pre Participation Screening and Exercise Prescription Practicum

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

Transcription:

DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35)

Table of Contents CATHETERIZATION IDENTIFICATION AND LINKING 3 DEMOGRAPHICS 5 PATIENT HISTORY 6 VITAL SIGNS 11 PHYSICAL EXAMINATION (PERFORMED PRIOR TO CARDIAC CATHETERIZATION) 12 LABORATORY RESULTS (PRIOR TO CARDIAC CATHETERIZATION, CLOSEST VALUE WITHIN 1 YEAR) 14 CATHETERIZATION PROCEDURE 15 CATHETERIZATION RESULTS 16 FOLLOW-UP: ALL DAYS TO EVENT VARIABLES ARE CENSORED IN DEC2014 19

Page 3 of 21 CATHETERIZATION IDENTIFICATION AND LINKING Variable Name (Type) RDAYSFROMINDEX (Numeric) Days from Index Cath N 83320 Mean (SD) 722.2 (1480.1) Median (25th, 75th) 0.0 (0.0, 623.5) Min, Max 0.0, 10442.0 For each unique patient included in the anonymized dataset, this variable records the days from the date of the first catheterization for that patient that shows significant coronary artery disease (CAD) that is recorded in the Duke Health System since 1/1/1985 to this catheterization date. This will be 0 if the catheterization record is the first recorded procedure. Because multiple caths may occur on the same day, it is possible for multiple caths to have the same value for this variable. Variable Name (Type) RSEQCATHNUM (Numeric) Patient's Sequential Cath Number N 83320 Mean (SD) 2.7 (3.0) Median (25th, 75th) 2.0 (1.0, 3.0) Min, Max 1.0, 46.0 For each unique patient included in the anonymized dataset, this variable records the sequential number for the current catheterization record. For example, if seqcathnum=1 then this is the first recorded Duke catheterization since 1/1/1985 for this patient that shows significant coronary artery disease (CAD). If seqcathnum=2, then this record is the second Duke catheterization procedure subsequent to the first one that showed significant CAD. Subsequent procedures are included in the dataset even if they do not show significant CAD. The database does not contain information on catheterizations received outside of the Duke Health System.

Page 4 of 21 CATHETERIZATION IDENTIFICATION AND LINKING Variable Name (Type) RSUBJID (Numeric) Subject ID N 83320 Mean (SD) 49956.1 (29018.4) Median (25th, 75th) 50182.0 (24702.0, 75088.5) Min, Max 0.0, 99997.0 Unique patient identifier (anonymized) Variable Name (Type) YRCATH_G (Numeric) Value Format Year of Cardiac Cath (categorized) 1 1985-1990 18475 / 83320 (22.2%) 2 1991-1994 13695 / 83320 (16.4%) 3 1995-1998 12983 / 83320 (15.6%) 4 1999-2002 13360 / 83320 (16.0%) 5 2003-2006 11635 / 83320 (14.0%) 6 2007-2010 7905 / 83320 (9.5%) 7 2011-2013 5267 / 83320 (6.3%) The calendar year in which this catheterization occurred. Years have been grouped: 1985-1990, 1991-1994, 1995-1998, 1999-2002, 2003-2006, 2007-2010, and 2011-2013.

Page 5 of 21 DEMOGRAPHICS Variable Name (Type) AGE_G (Numeric) Value Format Age in years (categorized) 1 18-24 44 / 83320 (0.1%) 2 25-29 142 / 83320 (0.2%) 3 30-34 571 / 83320 (0.7%) 4 35-39 1861 / 83320 (2.2%) 5 40-44 3882 / 83320 (4.7%) 6 45-49 6657 / 83320 (8.0%) 7 50-54 9227 / 83320 (11.1%) 8 55-59 11152 / 83320 (13.4%) 9 60-64 12118 / 83320 (14.5%) 10 65-69 13541 / 83320 (16.3%) 11 70-74 11444 / 83320 (13.7%) 12 75-79 7713 / 83320 (9.3%) 13 >=80 4968 / 83320 (6.0%) Age at the time of catheterization in years. Age has been grouped: 18-<25, 25-<30, 30-<35, 35-<40, 40-<45, 45-<50, 50-<55, 55-<60, 60-<65, 65-<70, 70-<75, 75-<80, and >=80 Variable Name (Type) GENDER (Numeric) Gender Value Format 0 Male 56570 / 83320 (67.9%) 1 Female 26750 / 83320 (32.1%) Sex as recorded in the Duke Health System

Page 6 of 21 DEMOGRAPHICS Variable Name (Type) RACE_G (Numeric) Race Value Format 1 Caucasian 66762 / 83320 (80.1%) 2 African American 11856 / 83320 (14.2%) 3 Other 3497 / 83320 (4.2%). Missing 1205 / 83320 (1.4%) Race as recorded in the Duke Health System PATIENT HISTORY Variable Name (Type) ACS (Numeric) Acute Coronary Syndrome Status Upon Presentation Value Format 0 No ACS 35198 / 83320 (42.2%) 1 STEMI 15315 / 83320 (18.4%) 2 Non-STEMI 6761 / 83320 (8.1%) 3 MI Unspecified 1854 / 83320 (2.2%) 4 Unstable Angina 24192 / 83320 (29.0%) Acute coronary syndrome, coronary artery disease symptom status at the time of presentation

Page 7 of 21 PATIENT HISTORY Variable Name (Type) CHFSEV (Numeric) Value Format CHF Severity (NYHA Class) 0 None 65028 / 83320 (78.0%) 1 I 2637 / 83320 (3.2%) 2 II 3974 / 83320 (4.8%) 3 III 5225 / 83320 (6.3%) 4 IV 3551 / 83320 (4.3%). Missing 2905 / 83320 (3.5%) Congestive heart failure severity is defined as the worst dyspnea or functional class in the previous 2 weeks, coded as the New York Heart Association (NYHA) classification. Congestive heart failure is defined as evidence of fluid retention due to cardiac causes. There should be a history of one or more of the following: exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, rales, pulmonary congestion on x-ray, or a ventricular gallop. Prior to 1994, a 6 week window was used for past CHF sx severity. Also, the classification included transient CHF as Class V. Transient CHF sx (Class V) has been converted to Class I. Class I - patient has cardiac disease but without resulting limitations of ordinary physical activity. Ordinary physical activity (e.g., walking several blocks or climbing stairs) does not cause undue fatigue, palpitation, dyspnea, or anginal pain. Limiting symptoms may occur with marked exertion. Class II - Patient has cardiac disease resulting in slight limitation of ordinary physical activity. Patient is comfortable at rest. Ordinary physical activity such as walking more than two blocks or climbing more than one flight of stairs results in limiting symptoms (e.g., fatigue, palpitation, dyspnea, or anginal pain). Class III - Patient has cardiac disease resulting in marked limitation of physical activity. Patient is comfortable at rest. Less than ordinary physical activity (e.g., walking one to two level blocks or climbing one flight of stairs) causes fatigue, palpitation, dyspnea, or anginal pain. Class IV - Patient has symptoms at rest that increase with any physical activity. Patient has cardiac disease resulting in inability to perform any physical activity without discomfort. Symptoms may be present even at rest. If any physical activity is undertaken, discomfort is increased. Variable Name (Type) DPCABG (Numeric) Days to Closest Previous Coronary Artery Bypass Surgery N 20476 Mean (SD) 2649.2 (2087.3) Median (25th, 75th) 2315.5 (890.5, 3954.0) Min, Max 1.0, 12950.0 Days from this catheterization to the closest preceding CABG. If no previous CABG is identified, then the value is set to missing. The previous procedure may not have been performed at Duke.

Page 8 of 21 PATIENT HISTORY Variable Name (Type) DPMI (Numeric) Days to Closest Previous Myocardial Infarction N 47058 Mean (SD) 996.3 (1944.5) Median (25th, 75th) 15.0 (2.0, 1058.0) Min, Max 0.0, 21802.0 Days from this catheterization to the closest preceding myocardial infarction. If no previous MI is identified, then the value is set to missing. Variable Name (Type) DPPCI (Numeric) Days to Closest Previous Percutaneous Coronary Intervention N 28336 Mean (SD) 867.8 (1291.5) Median (25th, 75th) 257.0 (89.0, 1148.0) Min, Max 0.0, 10978.0 Days from this catheterization to the closest preceding Percutaneous Coronary Intervention. If no previous PCI is identified, then the value is set to missing. The previous procedure may not have been performed at Duke. Variable Name (Type) HXANGINA (Numeric) History of Angina Value Format 0 No 9194 / 83320 (11.0%) 1 Yes 74005 / 83320 (88.8%). Missing 121 / 83320 (0.1%) History of anginal pain ever (excluding myocardial infarction pain)

Page 9 of 21 PATIENT HISTORY Variable Name (Type) HXCEREB (Numeric) Value Format History of Cerebrovascular Disease 0 No 73303 / 83320 (88.0%) 1 Yes 10017 / 83320 (12.0%) History of a stroke, a transient ischemic attack, hemiplegia, carotid surgery or stenting. An asymptomatic bruit is not included in the definition. Variable Name (Type) HXCHF (Numeric) Value Format History of CHF 0 No 60251 / 83320 (72.3%) 1 Yes 22054 / 83320 (26.5%). Missing 1015 / 83320 (1.2%) History of congestive heart failure not due to acute MI. This is defined as physician documentation or report of any of the following clinical symptoms of heart failure described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention; or the description of rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction. A low ejection fraction alone, without clinical evidence of heart failure does not qualify as heart failure. Variable Name (Type) HXCOPD (Numeric) Value Format History of COPD 0 No 77801 / 83320 (93.4%) 1 Yes 5519 / 83320 (6.6%) History of chronic obstructive pulmonary disease (COPD). The data collection form changed in 1990 when a specific option for COPD was added to the life-threatening comorbidity section of the form. Prior to this, information was collected as a free text field.

Page 10 of 21 PATIENT HISTORY Variable Name (Type) HXDIAB (Numeric) Value Format History of Diabetes 0 No 59026 / 83320 (70.8%) 1 Yes 24294 / 83320 (29.2%) A previous physician diagnosis of diabetes mellitus. The patient need not be under current therapy for diabetes, nor is current lab data or lab verification required. This does not differentiate between Type I and Type II diabetes. Variable Name (Type) HXHTN (Numeric) Value Format History of Hypertension 0 No 28301 / 83320 (34.0%) 1 Yes 55019 / 83320 (66.0%) Clinically significant hypertension by history. This does not depend upon a history of treatment; documentation by blood pressure determination is not required. Variable Name (Type) HXHYL (Numeric) History of Hyperlipidemia Value Format 0 No 32840 / 83320 (39.4%) 1 Yes 50480 / 83320 (60.6%) Previous diagnosis and/or treatment of hypercholesterolemia by a physician. Current lipid lab data was not used in the definition. Variable Name (Type) HXMI (Numeric) Value Format History of Myocardial Infarction 0 No 36262 / 83320 (43.5%) 1 Yes 47058 / 83320 (56.5%) History of a prior myocardial infarction. An MI is recorded during this admission and prior to catheterization only if the patient has documentation or typical evolutionary ECG changes with a consistent clinical history.

Page 11 of 21 PATIENT HISTORY Variable Name (Type) HXSMOKE (Numeric) History of Smoking Value Format 0 No 31115 / 83320 (37.3%) 1 Yes 52205 / 83320 (62.7%) History of smoking Variable Name (Type) NUMPRMI (Numeric) Number of Previous MIs N 83320 Mean (SD) 0.8 (0.9) Median (25th, 75th) 1.0 (0.0, 1.0) Min, Max 0.0, 10.0 Number of previous myocardial infarctions (counts 1 MI per day). VITAL SIGNS Variable Name (Type) DIASBP_R (Numeric) Diastolic Blood Pressure (mmhg) (as reported) N 78074 Mean (SD) 76.7 (14.0) Median (25th, 75th) 77.0 (68.0, 85.0) Min, Max 1.0, 210.0 Diastolic Blood Pressure (mmhg) as reported in patient record

Page 12 of 21 VITAL SIGNS Variable Name (Type) PULSE_R (Numeric) Heart Rate (bpm) (as reported) N 80491 Mean (SD) 73.1 (18.1) Median (25th, 75th) 70.0 (61.0, 80.0) Min, Max 17.0, 294.0 Heart Rate (bpm) as recorded in the patient record Variable Name (Type) SYSBP_R (Numeric) Systolic Blood Pressure (mmhg) (as reported) N 78407 Mean (SD) 137.1 (26.2) Median (25th, 75th) 135.0 (120.0, 153.0) Min, Max 40.0, 299.0 Systolic Blood Pressure (mmhg) as recorded in the patient record PHYSICAL EXAMINATION (PERFORMED PRIOR TO CARDIAC CATHETERIZATION) Variable Name (Type) CBRUITS (Numeric) Carotid Bruits Value Format 0 No 74120 / 83320 (89.0%) 1 Yes 8906 / 83320 (10.7%). Missing 294 / 83320 (0.4%) Carotid bruits detected during physical examination prior to catheterization. Bruits can be left, right, or bilateral.

Page 13 of 21 PHYSICAL EXAMINATION (PERFORMED PRIOR TO CARDIAC CATHETERIZATION) Variable Name (Type) HEIGHT_R (Numeric) Height (cm) (as reported) N 82468 Mean (SD) 171.8 (10.2) Median (25th, 75th) 173.0 (165.0, 180.0) Min, Max 82.0, 220.0 Height (cm) as recorded in the patient record Variable Name (Type) S3 (Numeric) Third Heart Sound Value Format 0 No 77874 / 83320 (93.5%) 1 Yes 3045 / 83320 (3.7%). Missing 2401 / 83320 (2.9%) S3 gallop or the third heart sound detected. Variable Name (Type) WEIGHT_R (Numeric) Weight (kg) (as reported) N 82499 Mean (SD) 83.8 (19.3) Median (25th, 75th) 82.0 (71.0, 94.0) Min, Max 30.0, 200.0 Weight in kilograms as recorded in the patient record

Page 14 of 21 LABORATORY RESULTS (PRIOR TO CARDIAC CATHETERIZATION, CLOSEST VALUE WITHIN 1 YEAR) Variable Name (Type) CREATININE_R (Numeric) Serum Creatinine (mg/dl) (as reported) N 63376 Mean (SD) 1.3 (1.6) Median (25th, 75th) 1.0 (0.9, 1.3) Min, Max 0.1, 138.0 Most recent Serum Creatinine (mg/dl) within 1 year preceding or on the day of this catheterization Variable Name (Type) HDL_R (Numeric) High Density Lipid (mg/dl) (as reported) N 32121 Mean (SD) 41.9 (31.7) Median (25th, 75th) 39.0 (33.0, 48.0) Min, Max 3.0, 5135.0 Most recent High Density Lipid (mg/dl) within 1 year preceding or on the day of this catheterization Variable Name (Type) LDL_R (Numeric) Low Density Lipid (mg/dl) (as reported) N 29260 Mean (SD) 104.3 (41.2) Median (25th, 75th) 100.0 (77.0, 127.0) Min, Max -37.0, 1313.0 Most recent Low Density Lipid (mg/dl) within 1 year preceding or on the day of this catheterization

Page 15 of 21 LABORATORY RESULTS (PRIOR TO CARDIAC CATHETERIZATION, CLOSEST VALUE WITHIN 1 YEAR) Variable Name (Type) TOTCHOL_R (Numeric) Total Cholesterol (mg/dl) (as reported) N 32739 Mean (SD) 178.5 (50.7) Median (25th, 75th) 174.0 (146.0, 205.0) Min, Max 0.4, 874.0 Most recent Total Cholesterol (mg/dl) within 1 year preceding or on the day of this catheterization CATHETERIZATION PROCEDURE Variable Name (Type) CATHAPPR (Numeric) Type of Cardiac Catheterization (approach) Value Format 0 Unknown 1711 / 83320 (2.1%) 1 Right Heart Only 1424 / 83320 (1.7%) 2 Left Heart Only 71105 / 83320 (85.3%) 3 Right and Left Heart 9080 / 83320 (10.9%) The catheterization approach: Right, left or both. Variable Name (Type) DIAGCATH (Numeric) Diagnostic Coronary Cath Value Format 0 No 3677 / 83320 (4.4%) 1 Yes 79643 / 83320 (95.6%) This is a diagnostic coronary cardiac catheterization (i.e., with an available arteriogram).

Page 16 of 21 CATHETERIZATION PROCEDURE Variable Name (Type) INTVCATH (Numeric) Interventional Coronary Cath Value Format 0 No 55229 / 83320 (66.3%) 1 Yes 28091 / 83320 (33.7%) Catheterization procedure which included some form of a percutaneous coronary intervention. CATHETERIZATION RESULTS Variable Name (Type) CORDOM (Numeric) Coronary Dominance Value Format 1 Left 6860 / 83320 (8.2%) 2 Right 74457 / 83320 (89.4%) 3 Balanced 1953 / 83320 (2.3%). Missing 50 / 83320 (0.1%) Dominance of the coronary tree: right, left or balanced. This is based on the coronary flow provided by the posterior descending artery. Variable Name (Type) GRAFTST (Numeric) Maximum Stenosis in any Graft N 13394 Mean (SD) 79.1 (33.6) Median (25th, 75th) 100.0 (75.0, 100.0) Min, Max 0.0, 100.0 Maximum percent stenosis detected across all coronary artery bypass grafts.

Page 17 of 21 CATHETERIZATION RESULTS Variable Name (Type) LADST (Numeric) Maximum Stenosis of the Left Anterior Descending Artery N 68160 Mean (SD) 71.9 (31.6) Median (25th, 75th) 90.0 (50.0, 95.0) Min, Max 0.0, 100.0 Maximum percent stenosis in all major arteries of the left anterior descending arterial system Variable Name (Type) LCXST (Numeric) Maximum Stenosis of the Left Circumflex Artery N 66466 Mean (SD) 61.9 (37.3) Median (25th, 75th) 75.0 (25.0, 95.0) Min, Max 0.0, 100.0 Maximum percent stenosis across the Left Circumflex Arterial system Variable Name (Type) LMST (Numeric) Maximum Stenosis of the Left Main Artery N 71815 Mean (SD) 14.0 (24.3) Median (25th, 75th) 0.0 (0.0, 25.0) Min, Max 0.0, 100.0 Maximum percent stenosis of the left main coronary artery

Page 18 of 21 CATHETERIZATION RESULTS Variable Name (Type) LVEF_R (Numeric) Left Ventricular Ejection Fraction (%) (as reported) N 47488 Mean (SD) 52.5 (14.2) Median (25th, 75th) 54.3 (43.0, 63.0) Min, Max 2.0, 95.7 Left Ventricular Ejection Fraction (%) as measured during left ventriculogram. Variable Name (Type) NUMDZV (Numeric) Value Format 0 None 5967 / 83320 (7.2%) 1 One 31786 / 83320 (38.1%) 2 Two 19362 / 83320 (23.2%) 3 Three 22450 / 83320 (26.9%). Missing 3755 / 83320 (4.5%) Number of Significantly Diseased Vessels (major arterial regions) Number of arterial systems with significant occlusion in a major segment. Prior to 7/1/2007, the threshold for defining a significant lesion was 75% or greater. Beginning 7/1/2007, the threshold for determining significance was changed to 50%. The coding of this variable is determined by physician judgment. Taken into account by the cathing physicians is the coronary dominance (left, right, or balanced). For example, the number of diseased vessels in a right dominant heart takes into consideration equally, the right coronary, left anterior descending, and left circumflex systems. However, left or balanced dominance as well as extent of left main disease will result in greater consideration of the left systems and potentially little or no contribution from the right coronary system. This variable will be missing if no arteriograms were performed during catheterization.

Page 19 of 21 CATHETERIZATION RESULTS Variable Name (Type) PRXLADST (Numeric) Maximum Stenosis of the Proximal Left Anterior Descending Artery N 68072 Mean (SD) 32.0 (38.0) Median (25th, 75th) 20.0 (0.0, 75.0) Min, Max 0.0, 100.0 Maximum percent stenosis in the proximal segmant of the left anterior descending arterial system Variable Name (Type) RCAST (Numeric) Maximum Stenosis of the Right Coronary Artery N 67000 Mean (SD) 66.6 (36.5) Median (25th, 75th) 80.0 (25.0, 100.0) Min, Max 0.0, 100.0 Maximum percent stenosis in the Right Coronary Arterial system FOLLOW-UP: ALL DAYS TO EVENT VARIABLES ARE CENSORED IN DEC2014 Variable Name (Type) DAYS2LKA (Numeric) Days to Last Known Alive N 83320 Mean (SD) 3689.7 (2640.5) Median (25th, 75th) 3337.0 (1470.0, 5500.0) Min, Max 0.0, 10937.0 Days from this catheterization to the last date that the patient was known to be alive. This will be zero for patients without any follow-up and whose vital status is alive. For deceased patients this is the number of days from this catheterization to date of death. Events and follow-up are censored in Dec2014.

Page 20 of 21 FOLLOW-UP: ALL DAYS TO EVENT VARIABLES ARE CENSORED IN DEC2014 Variable Name (Type) DEATH (Numeric) Vital Status at Last Contact Value Format 0 Alive 31908 / 83320 (38.3%) 1 Deceased 51412 / 83320 (61.7%) Indicator for whether the patient died or was still alive at end of follow-up. Follow-up censored in Dec2014. Variable Name (Type) DSCABG (Numeric) Days to First Subsequent Coronary Artery Bypass Surgery N 24470 Mean (SD) 905.6 (1576.5) Median (25th, 75th) 20.0 (3.0, 1291.0) Min, Max 0.0, 9742.0 Days from this catheterization to the first subsequent CABG. If the patient is never treated with CABG, then the value is set to missing. Event is censored in Dec2014. The subsequent procedure may not have been performed at Duke. Variable Name (Type) DSMI (Numeric) Days to First Subsequent Non-Fatal Myocardial Infarction N 12985 Mean (SD) 1956.3 (1923.7) Median (25th, 75th) 1398.0 (385.0, 2963.0) Min, Max 0.0, 9879.0 Days from this catheterization to the first subsequent MI. If there is no evidence of a subsequent MI, then the value is set to missing. Event is censored in Dec2014.

Page 21 of 21 FOLLOW-UP: ALL DAYS TO EVENT VARIABLES ARE CENSORED IN DEC2014 Variable Name (Type) DSPCI (Numeric) Days to First Subsequent Percutaneous Coronary Intervention N 47278 Mean (SD) 307.3 (970.3) Median (25th, 75th) 0.0 (0.0, 1.0) Min, Max 0.0, 10119.0 Days from this catheterization to the first subsequent PCI. If the patient is never treated with PCI, then the value is set to missing. Event is censored in Dec2014. The subsequent procedure may not have been performed at Duke. Variable Name (Type) DSSTROKE (Numeric) Days to First Subsequent Non-Fatal Stroke N 10155 Mean (SD) 2234.0 (2095.4) Median (25th, 75th) 1687.0 (429.0, 3493.0) Min, Max 0.0, 10580.0 Days from this catheterization to the first subsequent stroke. If there is no evidence of a subsequent stroke, then the value is set to missing. Event is censored in Dec2014. Variable Name (Type) FUPROTCL (Numeric) Value Format Patient on Follow-up Protocol 0 No 1613 / 83320 (1.9%) 1 Yes 81707 / 83320 (98.1%) Only a subset of the patients in this study were on a follow-up protocol. Follow-up protocol includes patient administered questionnaires, telephone contact and subsequent National Death Index submissions for non-responders. Follow-up protocol eligibility included all patients diagnosed at Duke with significant coronary disease or patients for whom follow-up was needed for other studies.